MANNHEIM, Germany, April 23, 2025 — Affimed N.V. (Nasdaq: AFMD), an immuno-oncology company in the clinical stage focused on empowering patients’ innate ability to combat cancer, announced that an abstract from the phase 2 LuminICE-203 study, which investigates its innate cell engager (ICE®) acimtamig combined with AlloNK® (AB-101), has been chosen for an oral presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting. The conference will be held in Chicago, Illinois, from May 30 to June 3, 2025. Furthermore, two abstracts concerning AFM24 used with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.
Details regarding the acimtamig oral presentation and AFM24 poster presentations are provided below:
| Abstract Title & Number | Date & Time | Session Type & Title |
| Results from the completed dose-finding portion of a phase 2 trial evaluating the innate cell engager acimtamig (AFM13) with AlloNK (AB-101) in patients with relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)
Abstract Number for Publication: 7008 |
May 30, 2025 2:45 PM-5:45 PM CDT |
Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
| Bispecific innate cell engager (ICE) AFM24 combined with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial findings from a phase 2a study
Abstract Number for Publication: 2609 |
June 2, 2025 1:30 PM-4:30 PM CDT |
Poster Session – Developmental Therapeutics—Immunotherapy
Poster Board: 256 |
| Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) featuring EGFR kinase domain mutations (EGFRmut): Preliminary results from a phase 2a study
Abstract Number for Publication: 2610 |
June 2, 2025 1:30 PM-4:30 PM CDT |
Poster Session – Developmental Therapeutics—Immunotherapy
Poster Board: 257 |
The complete abstracts will be available online starting May 22, 2025.
Further information about the 2025 ASCO Annual Meeting programs can be found online at .
About Affimed N.V.
Affimed (Nasdaq: AFMD) is an immuno-oncology company at the clinical stage. It focuses on restoring patients’ innate ability to fight cancer by harnessing the untapped potential of the innate immune system. The company’s innate cell engagers (ICE®) facilitate a tumor-targeted strategy to identify and eliminate a variety of hematologic and solid tumors. ICE® molecules are created using the company’s ROCK® platform, which reliably produces customized molecules that utilize the power of innate immune cells to destroy tumor cells. Several ICE® molecules are currently in clinical development, being evaluated as single therapies or in combination. Headquartered in Mannheim, Germany, Affimed is managed by a skilled team of biotechnology and pharmaceutical executives driven by the ambitious goal of preventing cancer from disrupting patients’ lives. For more details about the company’s team, pipeline, and partnerships, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail:
“`